Background Patients with coronavirus disease 2019 (COVID-19) exhibit high thrombotic risk.
The evidence on a potential independent prognostic role of antiplatelet treatment in those …

One of the major pathomechanisms of COVID-19 is the interplay of hyperinflammation and
disruptions in coagulation processes, involving thrombocytes. Antiplatelet therapy (AP) by …

Hypercoagulability and thrombosis caused by coronavirus disease 2019 (COVID‐19) are
related to the higher mortality rate. Because of limited data on the antiplatelet effect, we …

Introduction: Thromboembolic events are one of the important complications in COVID-19
patients, especially in severe cases. Aspirin affects platelet function by irreversibly inhibiting …

Background Aspirin is widely used as a cardioprotective agent due to its antiplatelet and anti-
inflammatory properties. The literature has assessed and evaluated its role in hospitalized …

Abstract Background and Objective Low-dose acetylsalicylic acid (ASA, aspirin) is a well-
known and frequently studied drug for primary and secondary prevention of disease due to …

Background Repurposing the use of aspirin to treat hospitalized patients with COVID-19 is a
sensible approach. However, several previous studies showed conflicting results. This meta …

Background Standard therapy for COVID-19 is continuously evolving. Autopsy studies
showed high prevalence of platelet-fibrin-rich microthrombi in several organs. The aim of the …

BACKGROUND: Coronavirus disease-2019 (COVID-19) is associated with
hypercoagulability and increased thrombotic risk in critically ill patients. To our knowledge …

Purpose The coronavirus disease 2019 (COVID-19) pandemic has shown unprecedented
impact world-wide since the eruption in late 2019. Importantly, emerging reports suggest an …